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Having decided on yeast as a production host, the choice of species is often the first question 
any researcher new to the field will ask. With over 500 known species of yeast to date, this 
could pose a significant challenge. However, in reality, only very few species of yeast have 
been employed as host organisms for the production of recombinant proteins. The two most 
widely used, Saccharomyces cerevisiae and Pichia pastoris, are compared and contrasted 
here. 
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1. Introduction 
Yeast is a single-celled, eukaryotic microbe that can grow quickly in complex or defined 
media (doubling times are typically 2.5 h in glucose-containing media) and is easier and less 
expensive to use for recombinant protein production than insect or mammalian cells (1). 
These positive attributes make yeast suitable for use in formats ranging from multi-well 
plates, shake flasks and continuously-stirred tank bioreactors to pilot plant and industrial 
scale reactors.  
 
The most commonly-employed species in the laboratory are Saccharomyces cerevisiae (also 
known as Baker’s or Brewer’s yeast) and some methylotrophic yeasts of the Pichia genus. In 
particular, S. cerevisiae and Pichia pastoris, which have both been genetically characterised 
(2-4), have been shown to perform the posttranslational disulphide bond formation and 
glycosylation (5-7) that is crucial for the proper functioning of some recombinant proteins. 
However, it is important to note that yeast glycosylation does differ from that in mammalian 
cells: in S. cerevisiae, O-linked oligosaccharides contain only mannose moieties, whereas 
higher eukaryotic proteins have sialylated O-linked chains. Furthermore S. cerevisiae is 
known to hyperglycosylate N-linked sites, which can result in altered protein binding, 
activity, and potentially yield an altered immunogenic response in therapeutic applications 
(8). In P. pastoris, oligosaccharides are of much shorter chain length (9) and a strain has been 
reported that can produce complex, terminally-sialylated or “humanised” glycoproteins (10).  
 
Despite these potential limitations, recombinant pharmaceuticals including insulin (11), 
interferon-alpha-2a (Reiferon Retard®) and vaccines against hepatitis B virus (Hepavax-Gene 
and Engerix-B®) (12) and Human papilloma virus (Gardasil®) (13, 14) have all been 
produced in yeasts for commercial use, demonstrating the importance of yeast as a host 
organism to the pharmaceutical industry.  The benefits and limitations of using S. cerevisiae 
and P. pastoris on a laboratory scale are addressed here and specific examples of their uses 
for the production of both soluble and membrane proteins are discussed.  
 
2. Saccharomyces cerevisiae 
S. cerevisiae is a single-celled, budding yeast, approximately 5–10 μm in size. Whilst it is 
commonly associated with the brewing and baking industries on account of its ability to 
produce ethanol and carbon dioxide, it is also the most widely-studied eukaryotic organism.  
The USA’s Food and Drug Administration (FDA) award of “generally recognized as safe” 
(GRAS) status to S. cerevisiae means that it is the most frequently-used species of yeast for 
the production of many functional proteins. These include several soluble antibody fragments 
and fusions (15-19) as well as membrane protein drug targets such as G protein-coupled 
receptors (20-25), ABC transporters (9, 26) and drug resistance proteins (27). 
 
2.1 Microbiology 
 (Insert Tables 1 and 2 here) 
 
The microbiology of S. cerevisiae is well understood and has been extensively reviewed 
elsewhere (28). In essence, it can grow both aerobically and anaerobically on a variety of 
carbon sources, is able to use ammonia or urea as a nitrogen source and also requires 
phosphorus and sulphur in its growth media. Certain metals such as calcium, iron, 
magnesium and zinc enhance its growth (29, 30): Tables 1 and 2 summarises typical growth 
media for S. cerevisiae. In culture it has a relatively short generation time, doubling its cell 
density approximately every 1.5–2.5 h at its preferred growth temperature of 30 °C.  
 
The ability of S. cerevisiae to produce ethanol hints at its unusual metabolism: in most 
eukaryotes, oxygen depletion controls the switch from a respiratory to a fermentative 
metabolism, but in S. cerevisiae this switch also occurs in response to a change in the external 
concentration of a fermentable carbon source such as glucose (31). During the type of aerobic 
batch cultivation on glucose often performed on a laboratory scale, S. cerevisiae displays a 
biphasic growth pattern (Figure 1). In the first respiro-fermentative phase, most of the 
glucose is converted to ethanol (32), which is subsequently consumed to produce carbon 
dioxide and water in the second phase. This has evolutionary advantages for S. cerevisiae, as 
the ethanol production phase is associated with a higher specific growth rate than the 
respiratory phase, providing a competitive advantage over other non-ethanol-producing 
organisms. Maximum recombinant protein yields are usually highest before yeast cells reach 
the end of this respiro-fermentative phase, before the so-called “diauxic shift” (Figure 1) into 
the respiratory phase (33). Consequently S. cerevisiae cells are typically harvested just before 
this diauxic shift in a protein production experiment, which can be readily assessed by 
monitoring the off-gas profile or the glucose concentration in the culture (24, 33). A 
respiratory strain of S. cerevisiae, TM6*, has been reported to have improved yield properties 
for both recombinant soluble and membrane proteins on account of its altered metabolism 
(24, 33). Its improved biomass yields, which are achieved at the expense of ethanol 
production, result in an increased volumetric yield of recombinant protein (34). 
 
(Insert Figure 1 here) 
 
2.2 Genetics 
S. cerevisiae was the first eukaryote to have its complete genome sequenced (2). The data are 
publicly available from the Saccharomyces Genome Database (SGD; 
www.yeastgenome.org), which is a scientific database of yeast molecular biology and 
genetics. The SGD provides detailed descriptions of the phenotypes of many mutant S. 
cerevisiae strains, many of which may have potential as protein production hosts, with links 
to supporting literature. Importantly, the SGD is fully annotated and is continually updated.  
 
Resources such as the SGD have facilitated an increased understanding of S. cerevisiae in 
general and, more specifically in the context of this discussion, of recombinant protein 
production in yeast cells. For example, since the production of high yields of functional 
recombinant proteins, particularly membrane proteins, remains a significant challenge we and 
others (35, 36) have focussed on characterising the cellular response to recombinant protein 
production. Identifying specific genes that exhibit an altered transcriptional profile, when the 
cell produces high yields of functional recombinant proteins, has been used to guide 
subsequent engineering of high yielding strains (24, 33, 37). This approach is strengthened by 
the availability of a complete set of single, non-essential gene deletion strains 
(EUROSCARF) as well as a strain collection of tetracycline-regulated essential genes (Open 
Biosystems). We demonstrated that increased yields of recombinant proteins can be achieved 
when specific members of these collections are used as host organisms (37). This permits the 
production of a recombinant protein to be compared in multiple strains simultaneously whilst 
gaining an improved knowledge of the molecular pathways involved in producing the 
protein. 
 
2.3 Molecular biology 
The DNA sequence encoding the target protein of interest is typically amplified via PCR 
either from genomic DNA or cDNA and then cloned into a suitable expression plasmid with 
or without signal sequences and fusion partners (see Chapters 3 and 4). Plasmids for S. 
cerevisiae can be sub-divided into three categories: low-copy number replicating plasmids; 
multi-copy number replicating plasmids and integrative plasmids (38, 39). These can, in turn, 
contain a range of different promoters of varying strengths that are either inducible or 
constitutive (Table 3). This means that a variety of different options can be tested in order to 
optimise the most suitable regime for recombinant protein production. However, it is 
important to ensure the stability of any transformants generated. For example, autonomous 
plasmids can be relatively unstable, yielding a heterogenous population of transformants that 
routinely require screening for the desired expression level, as well as being prone to genetic 
loss upon cell division. Furthermore high copy number plasmids may also result in 
expression levels that can overwhelm the host’s post-translational and secretory pathways, 
yielding misfolded and degraded protein. It may be possible to overcome some of these 
problems by integrating the expression cassette into the genome, thereby increasing its 
genetic stability (38, 39). 
 
(Insert Table 3 here) 
 
3. Pichia pastoris 
P. pastoris is used increasingly as the host cell of choice because of its ability to produce high 
yields of properly-folded proteins in exceptionally high density cultures. To achieve the 
highest possible biomass yields, it must be cultured in fully-controlled, continuously-stirred 
tank bioreactors (40). Its emergence as an alternative to S. cerevisiae is exemplified by the 
variety of heterologous proteins it has been used to produce in high yields, ranging from 
tetanus toxin and mouse epidermal growth factor (41-43) to membrane proteins including 
human ABC transporters, aquaporins and tetraspanins (44-46). A number of different 
protease deficient strains are also available (SMD1163, 1165 and 1168) that have been shown 
to exhibit reduced proteolysis of some recombinant proteins (47-50). 
 
3.1 Microbiology 
P. pastoris has a respiratory metabolism (Figure 1) and can be cultured to exceptionally high 
cell densities (hundreds of grams per litre) on glycerol-containing media (Tables 1 and 2), 
often yielding a culture resembling a paste at the end of an experiment (43, 51). The 
development of a respiratory strain of S. cerevisiae (TM6*) (24, 52) has gone someway to 
permitting similarly high cell density cultures of S. cerevisiae. However, while high cell 
density cultures are very attractive for increasing volumetric yields, productivity does not 
necessarily increase linearly with increased biomass yields, and in some situations may 
actually decrease (40, 53). For this reason, the ability to increase “per cell” yields is an area 
of active research, not only in P. pastoris but also in other host cells (34). 
 
P. pastoris is a methylotroph, which has two endogenous copies of the AOX gene; AOX1 
expression accounts for more than 90 % of the enzyme in the cell whilst AOX2 expression 
constitutes less than 10 % (see Chapter 15). It is these genes that permit the utilisation of 
methanol as a carbon source: using the Pichia Expression Kit marketed by Invitrogen 
Corporation, it is possible to use the AOX promoter to control heterologous gene expression, 
which is induced in the presence of methanol and repressed by glucose or glycerol (51). The 
careful control of the methanol induction regime is central to increasing yields per cell (40). 
Methanol metabolism is highly dependent on oxygen availability within the culture and it is 
widely accepted that the dissolved oxygen concentration (DO) should be maintained above 
20 % (54). This regime has been successfully employed to produce many different soluble 
and membrane proteins (40, 44, 46, 53, 55-57). 
 
Despite methanol induction being robust and tightly regulated, the potential risks associated 
with methanol use, such as its toxicity to cells at concentrations above 5 g L-1 and its 
volatility, have led researchers to investigate alternative promoters that do not require the use 
of methanol (58). Constitutive expression of heterologous genes can be achieved when 
cloned downstream of the glyceraldehyde 3-phosphate dehydrogenase (GAP) promoter (59, 
60), whilst strong induction via the formaldehyde dehydrogenase (FLD1) promoter has also 
been reported in the presence of methylamine as well as methanol (61). 
 
Like S. cerevisiae, P. pastoris is capable of producing disulfide bonded and glycosylated 
proteins (62). However, the glycosylation pattern is different in P. pastoris compared with S. 
cerevisiae (63): in P. pastoris N-linked oligosaccharides are usually no more than 20 residues 
in length compared with 50–150 residues in S. cerevisiae. In addition, P. pastoris lacks the 
mannosyl transferase which yields immunogenic α-1, 3-linked mannosyl terminal linkages in 
S. cerevisiae (64). 
 
3.2 Genetics 
P. pastoris is not considered to be as genetically amenable as S. cerevisiae, despite the fact 
that a genomic sequence of the GS115 strain has been commercially available since the mid 
2000’s. This is partly on account of a restrictive user contract that required all sequence 
information to be confidentially maintained. Despite this, genetic advances have been made 
as highlighted by the development of a “humanised” P. pastoris strain (10) capable of 
replicating the most essential glycosylation pathways found in mammalian cells and 
permitting the production of active recombinant erythropoietin. The open-access publication 
of the GS115 (3) and DSMZ 70382 (4) genomes in 2009 and their respective annotation at 
http://bioinformatics.psb.ugent.be/webtools/bogas/ and http://www.pichiagenome.org should 
make a significant impact in this area, as both sites permit free access to view the genomic 
sequences and use sequence resource software (65). 
 
3.3 Molecular biology 
As for S. cerevisiae, the target protein’s DNA sequence is often PCR amplified from genomic 
DNA or cDNA and cloned into an expression plasmid with or without signal sequences and 
fusion partners. The most widely-used P. pastoris expression vectors are designed to be 
maintained as stable, integrative elements in its genome (see Chapter 3). Examples include 
Invitrogen’s pPIC and pGAPZ series of vectors (Table 3). However, tranformants often 
exhibit heterogeneous expression levels and this necessitates the screening of many colonies 
to isolate high-yielding clones (see Chapter 7).  The limited number of episomal plasmids 
for P. pastoris to date has been predominantly due to plasmid instability during replication 
(66). Those that are available (Table 3) often utilise the constitutive GAP promoter (67, 68) 
and require the addition of selective antibiotic to maintain the vector. With the advent of open 
access genomic data it is hoped that there will be an increase in the number of episomal 
vectors that contain different auxotrophic markers for selection.   
 
4. Which species should I choose? 
There are benefits and drawbacks to using both S. cerevisiae and P. pastoris as hosts for 
recombinant protein production. For the production of secreted proteins, P. pastoris may be 
the best choice on account of its limited endogenous protein secretion and the number of 
different protease deficient strains available. However, the full benefit of P. pastoris will only 
be achieved if it is cultured under strictly-defined conditions, usually only achievable in 
continuously-stirred tank bioreactors. Therefore the optimal use of P. pastoris may require a 
more long term investment of time and equipment resources than for S. cerevisiae. In contrast 
S. cerevisiae provides a much wider range of resources (both strains and expression vectors) 
and is supported by a much more extensive literature than P. pastoris. Consequently, projects 
requiring a range of strains may benefit from using S. cerevisiae as the host. In our 
laboratory, we often start with P. pastoris and if the production is not straightforward, turn to 
S. cerevisiae to troubleshoot, thereby benefitting from the best attributes of the two hosts.  
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Figure 1: (a) A representative CO2 gas profile recorded in our laboratory, using a Tandem 
gas analyser, for a glucose-limited S. cerevisiae culture grown in a 2L Applikon bioreactor. 
The solid line shows the production of CO2 (%) and the dashed line shows the depletion of 
glucose (mmol). The respiro-fermentative and respiration phases are indicated, as is the 
diauxic shift between the 2 phases. (b) A CO2 gas profile recording for a P. pastoris glycerol 
fed-batch bioreactor culture induced at 28 h with a limiting amount of methanol. The solid 
line shows the production of CO2 (%) and the dashed line shows the optical density of the 
culture. 
Table 1: Composition of typical media for culturing S. cerevisiae and P. pastoris 
 




YPD (rich medium) 
 
10 g Bacto yeast extract  
20 g Bacto peptone 
20 g glucose 
 
YPG ( rich medium with non-fermentable 
carbon source) 
10 g Bacto yeast extract  
20 g Bacto peptone 
30 mL glycerol 
 
CSM (complete synthetic medium) 1.7 g Bacto yeast nitrogen base (without  amino 
acids) 
5 g ammonium sulphate 
20 g glucose 
100 mL 10× amino acid solution (see Table 2) 
2× CBS (Centralbureau voor 
Schimmelcultures medium) 
10 g ammonium sulphate  
6 g potassium dihydrogen phosphate 
1 g magnesium sulphate heptahydrate 
20 g glucose 
100 mL 1 M MES, pH 6  
200 ml 10× amino acid solution (see Table 2) 
2 mL vitamin solution (see Table 2) 
2 mL trace element solution (see Table 2) 
P. pastoris medium Components (L-1) 
 
BMGY (buffered glycerol-complex 
medium) 
 
10 g Bacto yeast extract 
20 g Bacto peptone 
100 mL 10× YNB (see Table 2) 
100 mL 1 M potassium phosphate (pH 6) 
2 mL 500× biotin (see Table 2) 
100 mL 10× glycerol (see Table 2) 
 
BMMY (buffered methanol-complex 
medium) 
 
10 g Bacto yeast extract 
20 g Bacto peptone 
100 mL 10× YNB (see Table 2) 
100 mL 1 M potassium phosphate (see Table 2) 
2 mL 500× biotin (see Table 2) 
100 mL 10× methanol (see Table 2) 
 
BSM (basal salts medium) 
 
26.7 mL phosphoric acid 
0.93 g calcium sulphate  
18.2 g potassium sulphate  
14.9 g magnesium sulphate heptahydrate  
4.13 g potassium hydroxide  
40 g glycerol  
4.35 mL PTM1 Salts (see Table 2) 
 
Table 2: Composition of stock solutions required to prepare media in Table 1 
S. cerevisiae medium stocks Components (L-1) 
 
 
10× amino acid solution 
 
200 mg L-adenine hemisulphate 
200 mg L-arginine hydrochloride 
200 mg L-histidine hydrochloride 
monohydrate 
300 mg L-isoleucine 
1000 mg L-leucine  
300 mg L-lysine hydrochloride 
200 mg L-methionine  
500 mg L-phenylalanine 
2000 mg L-threonine 
200 mg L-tryptophan 
300 mg L-tyrosine 
200 mg L-uracil 
1500 mg L-valine 
 
Vitamin solution (filter sterilised) 0.05 g biotin  
1 g calcium D-pantothenate 
1 g nicotinic acid 
25 g myo-inositol  
1 g thiamine hydrochloride  
1 g pyridoxol hydrochloride 
0.2 g D-amino benzoic acid 
 












15 g EDTA  
4.5 g zinc sulphate heptahydrate  
1 g magnesium chloride tetrahydrate 
0.3 g  colbalt (II) chloride hexahydrate 
0.3 g copper (II) sulphate pentahydrate 
0.4 g sodium molybdate dihydrate 
4.5 g calcium chloride dihydrate 
3 g iron sulphate heptahydrate 
1 g boric acid 
0.1 g potassium iodide  
P. pastoris medium stocks Components (L-1) 
 
10× YNB (filter sterilised) 
 
34 g yeast nitrogen base without ammonium 
sulphate and amino acids 
100 g ammonium sulphate 
 
500× biotin (filter sterilised) 200 mg biotin 
 
1 M potassium phosphate, pH6 868 mL 1 M KH2PO4; 132 ml 1 M K2HPO4 
(adjust to pH 6 with KOH and phosphoric 
acid) 
 
10× glycerol (10 %) 100 mL glycerol 
 
10× methanol (5 %; filter sterilised) 50 mL methanol 
 
PTM1 salts (filter sterilised) 
 
6 g cupric sulphate pentahydrate  
0.08 g sodium iodide  
3 g manganese sulphate monohydrate  
0.2 g sodium molybdate dihydrate  
0.02 g boric acid  
0.5 g cobalt chloride  
20 g zinc chloride  
65 g ferrous sulphate heptahydrate  
0.2 g biotin  




Table 3: Examples of expression vectors available for S. cerevisiae and P. pastoris 
 
Vector Yeast Selection 
marker 














pYX222 S. cerevisiae HIS3 TPI1 Constitutive Episomal  



















































































































Cell death Methanol 
induction 
Time (h) 
32 16 64 48 80 
Batch 
Starvation 
